- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00340990
Immune Responses to Mycobacterium Tuberculosis
Pilot Study of CD4+ T Cell Immune Responses to Mycobacterium Tuberculosis
This study, conducted at the University of Mali in the capital city of Bamako, will investigate how the body reacts to infection with Mycobacterium tuberculosis (MTB), the organism that causes tuberculosis. Tuberculosis is a major global health problem whose solution requires development of an effective vaccine. However, incomplete understanding of how immunity to MTB is acquired and measured limits vaccine development. This study will focus on certain immune system cells - CD4+ T cells - that appear to be very important in fighting tuberculosis.
Individuals 16 years of age and older who have or have not been exposed to either tuberculosis or HIV, or both, may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood tests, review of medical records and laboratory tests, and, if medically indicated, a chest x-ray. Individuals whose medical records indicate a past history of tuberculosis or a positive test for exposure to tuberculosis will have a tuberculin skin test. For this test, a few drops of fluid are placed under the skin to see if the immune system reacts to the substance, indicating previous exposure to MTB.
Participants will come to the University of Mali 10 times over a 1-year period - 7 times within the first 3 months of the study and then once every 3 months until 1 year after enrollment. At each study visit, they will be asked about their medical history and will donate 75 milliliters (about 1/3 cup) of blood, totaling 830 mL over the entire year. More blood may be requested if the participant's immune system reacts strongly to MTB in laboratory tests. No more than 450 mL (2 cups) of blood would be collected every 6 weeks; this amount is the Red Cross limit for regular blood donations every 6 weeks.
The blood samples will be used for tests that measure the level of immunity to tuberculosis. Genetic tests may be performed on blood cells to help interpret special tests of immunity. Because HIV-infected people are included in the study, the findings may also provide information on how HIV renders vulnerability to opportunistic infections, including tuberculosis.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Bamako, Mali
- University of Mali
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
- INCLUSION CRITERIA:
Ability to sign informed consent and willingness to comply with study requirements (including storage of blood specimens for future research on HIV, AIDS, MTB or the immune system).
CATEGORY-SPECIFIC MTB INCLUSION CRITERIA:
Group A (HIV-/MTB[BCG]) HIV ELISA(2) negative; BCG vaccinated with TST(2) less than 15 mm
Group B (HIV+/MTB[BCG]) HIV ELISA/WB(2) positive; BCG vaccinated with TST less than 5 mm
Group C (HIV-/MTB[pulm]) HIV ELISA negative; pulmonary MTB
Group D (HIV-/MTB[diss]) HIV ELISA negative; disseminated MTB
Group E (HIV+/MTB[pulm]) HIV ELISA/WB positive; pulmonary MTB
Group F (HIV+/MTB[diss]) HIV ELISA/WB positive; disseminated MTB
EXCLUSION CRITERIA:
Age less than 18 years (because of the risk for inducing protocol-related anemia)
Hg less than 7.5 g/dL
Latent MTB infection (as evidenced by a TST greater than 5 mm if HIV infected or greater than 15 mm if HIV uninfected) for arms A and B only.
Past history of treated MTB infection
Known or underlying bleeding disorder (due to risk of bleeding from venipuncture)
Psychiatric illness that might interfere with study compliance
Use of immunomodulators (including corticosteroids and IL-2) or cytotoxic agents (including hydroxyurea) within 45 days of signing consent and at any time during study
Small or difficult to access antecubital veins that make venipuncture difficult
Studienplan
Wie ist die Studie aufgebaut?
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Ellner JJ. Review: the immune response in human tuberculosis--implications for tuberculosis control. J Infect Dis. 1997 Nov;176(5):1351-9. doi: 10.1086/514132. No abstract available.
- Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis. 1993 Jun;167(6):1481-97. doi: 10.1093/infdis/167.6.1481.
- Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999 Oct 14;401(6754):708-12. doi: 10.1038/44385.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 999904009
- 04-I-N009
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Mycobacterium Tuberkulose
-
François SpertiniUniversity of OxfordAbgeschlossenTuberkulose | Mycobacterium Tuberculosis, Schutz vorSchweiz
-
Serum Institute of India Pvt. Ltd.Vakzine Projekt Management GmbHAktiv, nicht rekrutierendMycobacterium Tuberculosis-InfektionGabun, Kenia, Südafrika, Tansania, Uganda
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); WalimuRekrutierungTuberkulose, Lungen | Mycobacterium Tuberculosis-InfektionUganda
-
Assistance Publique - Hôpitaux de ParisAbgeschlossenKnochen- und osteoartikuläre Infektion aufgrund von MDR M. Tuberculosis-StämmenFrankreich
-
Global Alliance for TB Drug DevelopmentAbgeschlossenTuberkulose | Tuberkulose, Lungen | Lungenkrankheit | Multiresistente Tuberkulose | Arzneimittelsensitive Tuberkulose | Arzneimittelresistente Tuberkulose | Mycobacterium Tuberculosis-InfektionVereinigte Staaten
-
Global Alliance for TB Drug DevelopmentAbgeschlossenTuberkulose | Tuberkulose, Lungen | Lungenkrankheit | Multiresistente Tuberkulose | Arzneimittelsensitive Tuberkulose | Arzneimittelresistente Tuberkulose | Mycobacterium Tuberculosis-InfektionVereinigte Staaten
-
Oregon Health and Science UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Heart... und andere MitarbeiterRekrutierungMycobacterium Avium-KomplexVereinigte Staaten
-
Kevin WinthropPatient-Centered Outcomes Research Institute; Medical University of South Carolina und andere MitarbeiterRekrutierungMycobacterium Avium-Komplex | Nichttuberkulöse Mycobacterium-InfektionVereinigte Staaten, Kanada
-
Yale UniversityAbgeschlossenInfektion, Mycobacterium Avium-Intracellulare
-
Radboud University Medical CenterRekrutierungMycobacterium Avium Complex LungenerkrankungKorea, Republik von, Vereinigte Staaten, Kroatien, Japan, Niederlande